Features | Partner Sites | Information | LinkXpress
Sign In
RG Advertising
Schiller
TeraRecon

Low-Dose CT Screening Study Reveals Improved Diagnostic Performance for Lung Cancer

By Medimaging International staff writers
Posted on 09 Jul 2014
Image: A computed tomography (CT) scan showing lung cancer (Photo courtesy of Kevin Kavanagh, MD).
Image: A computed tomography (CT) scan showing lung cancer (Photo courtesy of Kevin Kavanagh, MD).
Investigators of a new study demonstrated good compliance and patient survival outcomes using a five-year low-dose computed tomography (LDCT) screening protocol in individuals at high-risk of developing lung cancer.

This COSMOS (Continuous Observation of SMOking Subjects) study protocol had fewer patients requiring additional diagnostic follow-up compared to other studies, including the US National Lung Cancer Screening Trial (NLST), with a minimal number of incorrect diagnoses.

The five-year survival rate for early diagnosed lung cancer is 50% but after the cancer has spread to distant regions it is only 4%. Recently, the NLST revealed a 20% lung cancer mortality reduction with LDCT compared to chest X-ray, which verified that early detection can decrease lung cancer deaths. However, few studies have comprehensively assessed the diagnostic performance, invasiveness and side effects of LDCT screening protocols with enduring follow-up.

The COSMOS study screened 5,203 asymptomatic high-risk subjects (age ≥ 50 and ≥ 20 pack years smoking history) who, based on the study criteria, either went on to other diagnostic procedures (CT, positron emission tomography [PET], or surgery) to verify lung cancer, or were rescreened every year for the next four years. All subjects were clinically followed for a median of 5.2 years.

The study’s findings, reported in the July 2014, issue of the Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, show that overall, 79% of the participants remained on the study for five years and only 6.4% required a procedure beyond the yearly LDCT. Primary lung cancer was diagnosed in 175 patients and 78% of these were diagnosed with localized disease. Because of the size and long follow-up, there were 23,116 person-years of observation. Therefore, the overall lung cancer detection rate was 0.76 per 100 person-years.

Out of the 204 invasive diagnostic procedures, 29 were benign for lung cancer, 34 had minor complications, 12 major complications and one postoperative fatality was reported. There were 14 instances where the lesions were not diagnosed as cancer, but were later determined to be cancer on subsequent yearly screening. A high proportion of the cancers (87%) were treated with intent to cure and the overall five-year survival was 78%.

“The results of the COSMOS workup protocol for indeterminate nodules detected with LDCT screening are encouraging, particularly the low recall and delayed diagnosis rates as well as the good long-term survival,” said Dr. Giulia Veronesi, Dr. Giulia Veronesi from the department of thoracic surgery, European Institute of Oncology (Milan, Italy) is a member of the International Association for the Study of Lung Cancer (IASLC), and lead author of the study. “However, the workup can still be improved, possibly by tailoring the screening interval to the risk of the individual being screened using a risk evaluation algorithm that will hopefully also include in the near future molecular markers like a microRNA expression signature in serum.”

Related Links:

European Institute of Oncology



Channels

MRI

view channel
Image: Construction Workers Building CUBRIC (Photo courtesy of Cardiff University).

New Brain Research Imaging Center Under Construction in Cardiff University

Cardiff University (Cardiff, UK) has begun building an advanced MR imaging technology center, with the help of Siemens Healthcare (Erlangen, Germany). The center will use the latest brain imaging and brain... Read more

Nuclear medicine

view channel

Construction of Australian Nuclear Medicine Production Plant Begins

The new facility is being built as part of the Australian Nuclear Science and Technology Organisation (ANSTO; NSW, Australia) Nuclear Medicine (ANM) project, and includes an investment of USD 168.8 by the Australian government. The ANM project also includes the construction of a Synroc plant for treatment of radioactive... Read more

General/Advanced Imaging

view channel
Image: Measuring the Magnetic Activity in the Brain of a Child, Using a MEG machine. (Photo courtesy of Children\'s Hospital of Philadelphia).

Study Suggests Language Delay Linked to Chromosome Deletion in Children with Neurological Disorders

A study found that children with neuro-developmental problems born with DNA duplications or deletions on part of chromosome 16, show measurable delays in their ability to process sound and language.... Read more

Imaging IT

view channel

European Governments Adopting Country-Specific Electronic Health Record Implementation Models

Frost & Sullivan (Mountain View, CA, USA) has released a new analysis of the Electronic Health Records (EHR) market in Europe. The study analyzes the hospital and ambulatory EHR market. According to the study, the market earned revenues of USD 2.74 billion in 2014, and is expected to reach USD 3.69 billion in 2020.... Read more

Industry News

view channel

Long-Term Contract for Telehealth Services Awarded by German Health Insurance Company

Almeda (Munich, Germany), a subsidiary of SHL Telemedicine (Tel Aviv, Israel), has won a public tender for an 8-year contract worth EUR 16–20 million offered by Barmer GEK (Wuppertal, Germany), a health insurance company, to provide telehealth services to clients insured at Barmer. Barmer GEK was already a long-term client... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.